Iovance Biotherapeutics, Inc. IOVA stock is trading higher. The company recently announced updated clinical data for treating frontline advanced melanoma.
What Happened: On Thursday, Iovance revealed updated clinical findings for lifileucel in conjunction with pembrolizumab as a treatment for frontline advanced melanoma, as well as implementation data, to be presented at the 2024 ASCO Annual Meeting.
Results from the clinical trial, specifically IOV-COM-202 trial’s Cohort 1A, were published in an abstract and showcased promising outcomes in frontline advanced melanoma patients new to immune checkpoint inhibitor therapy.
The findings from the 23 patients include a 65.2% overall response rate with 7 complete responses and 8 partial responses.
In addition, all evaluable patients demonstrated regression of their target lesions.
The clinical and safety results of Cohort 1A further support TILVANCE-301 trial’s purpose. TILVANCE-301 is a worldwide Phase 3 trial aiming to accelerate full U.S. approval of lifileucel in combination with pembrolizumab for treating frontline advanced melanoma.
The 2024 ASCO Annual Meeting will be held at McCormick Place in Chicago, Illinois and online from May 31 to June 4.
Related Link: Novo Nordisk Releases Data Showing Ozempic For Diabetes Slows Kidney Disease Progression
Separately, HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance with a Buy and maintains $32 price target.
IOVA Price Action: At the time of publication Iovance shares were trading .66% higher at $10.29, according to data from Benzinga Pro.
Image: 911612 from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
